# Enviri Corp: financial statements, quarterly

NVRI · NYSE · CIK 2104052 · [Utilities](/sectors/utilities.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nvri.md) · [Financials](/companies/nvri/financials.md) · [Filings](/companies/nvri/filings.md) · [Insiders](/companies/nvri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvri/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [548](/filings/0002104052-26-000081.md) | [316](/filings/0002104052-26-000128.md) | [550](/filings/0002104052-26-000081.md) | [187](/filings/0002104052-26-000128.md) |
| Research and development | $m | [0.5](/filings/0002104052-26-000081.md) | [0.8](/filings/0002104052-26-000128.md) | [0.5](/filings/0002104052-26-000081.md) | [0.7](/filings/0002104052-26-000128.md) |
| Selling, general and administrative | $m | [89.1](/filings/0002104052-26-000081.md) | [53.8](/filings/0002104052-26-000128.md) | [91.5](/filings/0002104052-26-000081.md) | [49.1](/filings/0002104052-26-000128.md) |
| Operating income | $m | [29.3](/filings/0002104052-26-000081.md) | [(31.6)](/filings/0002104052-26-000128.md) | [0.8](/filings/0002104052-26-000081.md) | [(244)](/filings/0002104052-26-000128.md) |
| Interest expense | $m | [26.6](/filings/0002104052-26-000081.md) | [8.7](/filings/0002104052-26-000128.md) | [27.8](/filings/0002104052-26-000081.md) | [8.2](/filings/0002104052-26-000128.md) |
| Income tax | $m | [2.0](/filings/0002104052-26-000081.md) | [(0.9)](/filings/0002104052-26-000128.md) | [(24.4)](/filings/0002104052-26-000081.md) | [40.5](/filings/0002104052-26-000128.md) |
| Net income | $m | [(9.0)](/filings/0002104052-26-000081.md) | [(47.8)](/filings/0002104052-26-000128.md) | [(10.7)](/filings/0002104052-26-000081.md) | [(396)](/filings/0002104052-26-000128.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0002104052-26-000081.md) | [(1.78)](/filings/0002104052-26-000128.md) | [(0.13)](/filings/0002104052-26-000081.md) | [(14.21)](/filings/0002104052-26-000128.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0002104052-26-000081.md) | [(1.78)](/filings/0002104052-26-000128.md) | [(0.13)](/filings/0002104052-26-000081.md) | [(14.21)](/filings/0002104052-26-000128.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [102](/filings/0002104052-26-000081.md) | not reported | [103](/filings/0002104052-26-000128.md) | [106](/filings/0002104052-26-000081.md) | [253](/filings/0002104052-26-000128.md) |
| Current assets | $m | not reported | not reported | not reported | [721](/filings/0002104052-26-000128.md) | [722](/filings/0002104052-26-000081.md) | [791](/filings/0002104052-26-000128.md) |
| Total assets | $m | not reported | not reported | not reported | [2,743](/filings/0002104052-26-000128.md) | [2,704](/filings/0002104052-26-000081.md) | [1,723](/filings/0002104052-26-000128.md) |
| Current liabilities | $m | not reported | not reported | not reported | [634](/filings/0002104052-26-000128.md) | [641](/filings/0002104052-26-000081.md) | [551](/filings/0002104052-26-000128.md) |
| Total liabilities | $m | not reported | not reported | not reported | [2,447](/filings/0002104052-26-000128.md) | [2,429](/filings/0002104052-26-000081.md) | [1,040](/filings/0002104052-26-000128.md) |
| Long-term debt | $m | not reported | not reported | not reported | [1,480](/filings/0002104052-26-000128.md) | [1,557](/filings/0002104052-26-000081.md) | [381](/filings/0002104052-26-000128.md) |
| Current portion of debt | $m | not reported | not reported | not reported | [14.4](/filings/0002104052-26-000128.md) | [25.8](/filings/0002104052-26-000081.md) | [8.5](/filings/0002104052-26-000128.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | [11.5](/filings/0002104052-26-000128.md) | [8.7](/filings/0002104052-26-000081.md) | [0.1](/filings/0002104052-26-000128.md) |
| Shareholders' equity | $m | [430](/filings/0002104052-26-000128.md) | [433](/filings/0002104052-26-000128.md) | [400](/filings/0002104052-26-000128.md) | [255](/filings/0002104052-26-000128.md) | [233](/filings/0002104052-26-000081.md) | [639](/filings/0002104052-26-000128.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [6.6](/filings/0002104052-26-000081.md) | [22.0 d](/filings/0002104052-26-000128.md) | [21.5](/filings/0002104052-26-000081.md) | [(297) d](/filings/0002104052-26-000128.md) |
| Capital expenditure | $m | [21.6](/filings/0002104052-26-000081.md) | [39.0 d](/filings/0002104052-26-000128.md) | [33.7](/filings/0002104052-26-000081.md) | [34.7 d](/filings/0002104052-26-000128.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [80.3](/filings/0002104052-26-000081.md) | [26.9](/filings/0002104052-26-000128.md) | [82.3](/filings/0002104052-26-000081.md) | [27.9](/filings/0002104052-26-000128.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,190,119 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0002104052-26-000128.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.